οƵ

Barbara M. Wirostko
( out of 107 reviews )

Barbara M. Wirostko, MD

Languages spoken: English

Clinical Locations

John A. Moran Eye Center

Salt Lake City
801-581-2352

Redstone οƵ Center

Park City
435-658-9200

  • Barbara M. Wirostko, MD, FARVO, treats glaucoma and comprehensive ophthalmology patients, specializes in clinical research, and advises drug development for glaucoma pharmaceutical therapies. She has specialized fellowship training in glaucoma, is a board-certified ophthalmologist, and is a Fellow of The Association of Research in Vision and Ophthalmology (ARVO).

    Her research interest is in novel glaucoma therapeutics, sustained delivery of therapeutics for ocular pathologies, and better understanding the genetics and associated systemic diseases of exfoliative syndrome, a common cause of open-angle glaucoma. As a serial entrepreneur for biotech startups, she has received millions in grants as the principal investigator (PI) for funding from the Department of Defense and National Science Foundation.

    Dr. Wirostko has scored in the top 10 percent nationwide for patient satisfaction. Her honors include Moran’s Clinical Faculty of the Year Award in 2015 and the Third Annual Distinguished Alumni Award from the Edward S. Harkness Eye Institute, Columbia οƵ.

    Her professional and scientific experience includes serving as associate editor for Ophthalmology Glaucoma, Acta Ophthalmologica, and Journal of Glaucoma. She’s an active committee member for ARVO and a scientific advisor for the California Institute of Regenerative Medicine, The Glaucoma Foundation, and the Glaucoma Research Foundation.

    Dr. Wirostko’s numerous grants include a new two-year project funded by a BrightFocus Foundation National Glaucoma Research award of nearly $180,000. The research project, “Prognostic Factors and Predictive Markers of Progression to Exfoliation Glaucoma in Exfoliation Syndrome,” will include a multi-disciplinary team of experts. She will serve as co-PI with Karen Curtin, PhD, MStat, with the Utah Population Database.

    Get to know Dr. Wirostko by watching her .

    Specialties

    Board Certification

    American Board of Ophthalmology

    Patient Rating

    5.0 /5
    ( out of 107 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 02, 2024
    REDSTONE HEALTH CENTER

    Very pleased with her care. I feel very confident with her diagnosis

    July 19, 2024
    REDSTONE HEALTH CENTER

    Very informative and encouraging, explaining everything in detail.

    July 18, 2024
    REDSTONE HEALTH CENTER

    Very compassionate extremely knowledgeable and thorough did not feel rushed at all. Would highly recommend Dr Wirostko to other patients

    July 13, 2024
    REDSTONE HEALTH CENTER

    Always appears to have time for me as a patient. Very concerned about my individual problem.

    June 22, 2024
    REDSTONE HEALTH CENTER

    Dr. Wirostko is a consummate professional with an excellent bedside manner

    June 20, 2024
    REDSTONE HEALTH CENTER

    Dr. Wirostco is excellent and very professional.

    June 20, 2024
    REDSTONE HEALTH CENTER

    Dr. Wirostko is the best of the best.

    June 13, 2024
    REDSTONE HEALTH CENTER

    Barbara is excellent. She explains options in clear ways so that you understand.

    May 30, 2024
    REDSTONE HEALTH CENTER

    Dr Wirostko explained what she would be doing and everything went very smoothly.

    See More Patient Comments

  • Barbara M. Wirostko, MD, FARVO, treats glaucoma and comprehensive ophthalmology patients, specializes in clinical research, and advises drug development for glaucoma pharmaceutical therapies. She has specialized fellowship training in glaucoma, is a board-certified ophthalmologist, and is a Fellow of The Association of Research in Vision and Ophthalmology (ARVO).

    Her research interest is in novel glaucoma therapeutics, sustained delivery of therapeutics for ocular pathologies, and better understanding the genetics and associated systemic diseases of exfoliative syndrome, a common cause of open-angle glaucoma. As a serial entrepreneur for biotech startups, she has received millions in grants as the principal investigator (PI) for funding from the Department of Defense and National Science Foundation.

    Dr. Wirostko has scored in the top 10 percent nationwide for patient satisfaction. Her honors include Moran’s Clinical Faculty of the Year Award in 2015 and the Third Annual Distinguished Alumni Award from the Edward S. Harkness Eye Institute, Columbia οƵ.

    Her professional and scientific experience includes serving as associate editor for Ophthalmology Glaucoma, Acta Ophthalmologica, and Journal of Glaucoma. She’s an active committee member for ARVO and a scientific advisor for the California Institute of Regenerative Medicine, The Glaucoma Foundation, and the Glaucoma Research Foundation.

    Dr. Wirostko’s numerous grants include a new two-year project funded by a BrightFocus Foundation National Glaucoma Research award of nearly $180,000. The research project, “Prognostic Factors and Predictive Markers of Progression to Exfoliation Glaucoma in Exfoliation Syndrome,” will include a multi-disciplinary team of experts. She will serve as co-PI with Karen Curtin, PhD, MStat, with the Utah Population Database.

    Get to know Dr. Wirostko by watching her .

    Board Certification and Academic Information

    Academic Departments Ophthalmology & Visual Sciences -Adjunct
    Board Certification
    American Board of Ophthalmology

    Education history

    Fellowship Glaucoma - The New York Hospital, Cornell Medical Center Fellow
    Ophthalmology - Columbia Presbyterian Medical Center, Edward S. Harkness Eye Institute Resident
    Internship Hackensack Medical Center Intern
    Medicine - Columbia οƵ M.D.
    Undergraduate Microbiology - Cornell οƵ B.A.

    Selected Publications

    Journal Article

    1. Chauhan MZ, Elhusseiny AM, Marwah S, Sallam AB, Stein JD, Kishor KS, SOURCE Consortium, Amin S, Edwards PA, Srikumaran D, Woreta F, Schultz JS, Shrivastava A, Ahmad B, Pasquale L, Bryar PJ, French DD, Hribar M, Thomas M, Vanderbeek BL, Pershing S, Wang SY, Deiner M, Sun C, Patnaik J, Subramanian P, Munir S, Munir W, Stein JD, De Lott L, Ramachandran R, Feldman R, Stagg BC, Wirostko B, McMillian B, Sheybani A, Sarrapour S, Harris-Nwanyanwu K (2024). Incidence of Uveitis Following Initiation of Prostaglandin Analogs Versus Other Glaucoma Medications: A Study from the SOURCE Repository. Ophthalmol Glaucoma. ()
    2. Pompoco C, Paulson C, Fino N, Taylor S, Patil A, Conley M, Barker J, Ritch R, Hageman GS, Curtin K, Wirostko B (2024). Risk of Age-Related Macular Degeneration in Patients with Exfoliation Syndrome: The Utah Project on Exfoliation Syndrome (UPEXS) . Journal of Clinical & Translational Ophthalmology, 2(4), 140-154.
    3. Curtin K, Stein JD, Stagg BC, Fino N, Conley M, Johnson T, Patil A, Paulson C, Pompoco C, Wirostko BM (2024). Identifiable historic and observable factors may predict progression to exfoliation glaucoma in newly-diagnosed exfoliation patients. Ophthalmol Glaucoma. ()
    4. Riina N, Harris A, Siesky BA, Ritzer L, Pasquale LR, Tsai JC, Keller J, Wirostko B, Arciero J, Fry B, Eckert G, Verticchio Vercellin A, Antman G, Sidoti PA, Guidoboni G (2024). Using Multi-Layer Perceptron Driven Diagnosis to Compare Biomarkers for Primary Open Angle Glaucoma. Invest Ophthalmol Vis Sci, 65(11), 16. ()
    5. Polski A, Long T, Stagg BC, Wirostko B (2024). Uveitis-Glaucoma-Hyphema Syndrome from Subtle Malposition of a Hydrus Microstent. J Glaucoma. ()
    6. Polski A, Liu KC, Gupta D, Grewal DS, Horns J, Wirostko BM, Stagg BC (2023). Incident glaucoma and ocular hypertension after periocular and intravitreal steroid injections: a claims-based analysis. BMJ Open Ophthalmol, 8(1). ()
    7. Delsoz M, Raja H, Madadi Y, Tang AA, Wirostko BM, Kahook MY, Yousefi S (2023). The Use of ChatGPT to Assist in Diagnosing Glaucoma Based on Clinical Case Reports. Ophthalmol Ther. ()
    8. Patil A, Conley M, Pompoco C, Paulson C, Taylor S, Swiston C, Herrick JS, Ritch R, Curtin K, Wirostko B (2022). Abdominal aortic aneurysm and exfoliation syndrome in Utah. Acta Ophthalmol, 101(4), 449-456. ()
    9. Roy Chowdhury U, Pervan-Steel CL, Sheeler R, Sookdeo HK, Rogers B, Casale R, Dosa PI, Htoo T, Wirostko BM, Fautsch MP (2023). Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent. J Ocul Pharmacol Ther, 39(5), 332-346. ()
    10. Patil A, Conley M, Paulson C, Pompoco C, Wallace R, Swiston RR, Curtin K, Wirostko B (2022). Abdominal aortic aneurysm and exfoliation syndrome: A literature review comparing single site findings . Acta Ophthalmol (Copenh), 101(5), 478-484.
    11. Paulson C, Barker DJ, Pompoco C, Taylor S, Conley M, Patil A, Amakiri N, Stagg B, Ritch R, Kang JH, Wiggs JL, Curtin K, Wirostko B (2022). Association of Non-Melanoma Skin Carcinomas and UV Exposure with Exfoliation Syndrome in Utah. Med Res Arch, 10(10).
    12. Guidoboni G, Nunez R, Keller J, Wikle C, Robinson EL, Verticchio A, Siesky B, Oddone F, Quaranta L, Wirostko B, Topouzis F, Cheng C-Y, Januleviciene I, Wegner A, Antman G, Jones C, Harris A (2022). Precision medicine and glaucoma management: how mathematical modeling and artificail intelligence help in clinical practice. Online Journal. Expert Rev Ophthalmol, 17(5).
    13. Patil A, Swiston C, Wallace RT, Paulson C, Conley ME, McCoy L, Chaya C, Wirostko B (2022). Exfoliation Syndrome and Exfoliation Glaucoma in the Navajo Nation. An ARVO publication. ARVO Annual Meeting Abstract Search and Program Planner, 63(7), 1641.
    14. Levin AM, McGlumphy EJ, Chaya CJ, Wirostko BM, Johnson TV (2022). The utility of home tonometry for peri-interventional decision-making in glaucoma surgery: Case series. Am J Ophthalmol Case Rep, 28, 101689. ()
    15. Wirostko BM, Curtin K, Taylor SC, Paulson C, Pompoco C, Besch BM, Ranjan R, Ritch R (2022). Risk of atrial fibrillation is increased in patients with exfoliation syndrome: the Utah project on exfoliation syndrome (UPEXS) . Acta Ophthalmol, 100(4).
    16. Huang JJ, Geduldig JE, Jacobs EB, Tai TT, Ahmad S, Chadha N, Buxton DF, Vinod K, Wirostko BM, Kang JH, Wiggs JL, Ritch R, Pasquale LR (2022). Head and Neck Region Dermatological Ultraviolet-Related Cancers are Associated with Exfoliation Syndrome in a Clinic-Based Population . Ophthalmol Glaucoma, 5(6), 663-671.
    17. Pervan-Steel CL, Chowdhury UR, Sookdeo HK, Casale RA, Dosa PI, Htoo TM, Fautsch MP, Wirostko BM (2022). Ocular Hypotensive Properties and Biochemical Profile of QLS-101, a Novel ATP-Sensitive Potassium (KATP) Channel Opening Prodrug. Invest Ophthalmol Vis Sci, 63(4), 26.
    18. Sharma A, Riaz KM, Gill MS, Patnaik A, Ulahannan SV, Wang JS, Gombos DS, Ang Q, Cicic D, Bergonio GR, Zhang C, Wirostko BM (2021). Reversible HER2 antibody-drug conjugate-induced ocular toxicity. Can J Ophthalmol, 57(2), 118-126. ()
    19. Paulson C, Thomas SC, Gonzalez O, Taylor S, Swiston C, Herrick JS, McCoy L, Curtin K, Chaya CJ, Stagg BC, Wirostko BM (2022). Exfoliation Syndrome in Baja Verapaz Guatemala: A Cross-Sectional Study and Review of the Literature. J Clin Med, 11(7). ()
    20. Pompoco CJ, Curtin K, Taylor S, Paulson C, Shumway C, Conley M, Barker DJ, Swiston C, Stagg B, Ritch R, Wirostko BM (2021). Summary of Utah Project on Exfoliation Syndrome (XPEXS): Using a large database to identify systemic comorbidities . BMJ Open Ophthalmol, 6(1), e000803.
    21. Levin AM, Chaya CJ, Kahook MY, Wirostko BM (2021). Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short and Long-term Considerations. J Glaucoma, 30(12), 1019-1026.
    22. Levin AM, Vezina D, Wirostko BM (2021). Home-Based Intraocular Pressure Measurements: Tracing a Parallel with Out-of-Office Blood Pressure Measurement. Ophthalmol Glaucoma, 4(3), 235-237.
    23. Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, Hartnett ME, Cummins M, Morris A, Hess R, Kawamoto K (2020). Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. Ophthalmol Glaucoma, 4(1), 5-9. ()
    24. Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, Hartnett ME, Cummings M, Morris A, Hess R, Kawamoto K (2020). Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. Ophthalmol Glaucoma, 4(1), 5-9.
    25. Kang JH, VoPham T, Laden F, Rosner BA, Wirostko B, Ritch R, Wiggs JL, Qureshi A, Nan H, Pasquale LR (2021). Cohort Study of Nonmelanoma Skin Cancer and the Risk of Exfoliation Glaucoma. J Glaucoma, 29(6), 448-455. ()
    26. Wirostko B, Mann B, Stirland D (2020). Re: "Cross-Linked Hyaluronic Acid as Tear Film Substitute" by Posarelli et al. ( J Ocul Pharmacol Ther 2019;35(7):381-387) . J Ocul Pharmacol Ther, 36(4), 205.
    27. Perez VL, Wirostko B, Korenfeld M, From S, Raizman M (2019). Ophthalmic Drug Delivery Using Iontophoresis: Recent Clinical Applications. J Ocul Pharmacol Ther, 36(2), 75-87. ()
    28. Taylor SC, Bernhisel AA, Curtin K, Allingham RR, Ritch R, Wirostko BM (2018). Association between Chronic Obstructive Pulmonary Disease and Exfoliation Syndrome: The Utah Project on Exfoliation Syndrome. Ophthalmol Glaucoma, 2(1), 3-10. ()
    29. Besch BM, Curtin K, Ritch R, Allingham RR, Wirostko BM (2018). Association of Exfoliation Syndrome With Risk of Indirect Inguinal Hernia: The Utah Project on Exfoliation Syndrome. JAMA Ophthalmol, 136(12), 1368-1374. ()
    30. Wirostko B, Allingham R, Wong J, Curtin K (2018). Utah Project on Exfoliation Syndrome (UPEXS): Insight Into Systemic Diseases Associated With Exfoliation Syndrome. J Glaucoma, 27 Suppl 1, S75-S77. ()
    31. Durrie DS, Wolsey D, Thompson V, Assang C, Mann B, Wirostko B (2018). Ability of a new crosslinked polymer ocular bandage gel to accelerate reepithelialization after photorefractive keratectomy. J Cataract Refract Surg, 44(3), 369-375. ()

    Review

    1. Asrani SG, McGlumphy EJ, Al-Aswad LA, Chaya CJ, Lin S, Musch DC, Pitha I, Robin AL, Wirostko B, Johnson TV (2024). The relationship between intraocular pressure and glaucoma: An evolving concept. [Review]. Prog Retin Eye Res, 103, 101303. ()

    Editorial

    1. Johnson C, Pasquale LR, Wirostko B (2024). Glucagon-Like Peptide 1 Receptor Agonists: A Role in Glaucoma? Ophthalmol Glaucoma, 7(5), 419-421. ()
    2. Johnson C, Pasquale LR, Wirostko B (2024). Glucagon-Like Peptide 1 Receptor Agonists: A Role in Glaucoma? Ophthalmol Glaucoma, 7(5), 419-421. ()
    3. Mai AP, Wirostko B, Fitch S, Hansen K, Imbrescia W, Stagg BC (2023). Using Technology to Address Ophthalmic Technician Shortages in Glaucoma Clinics. Ophthalmol Glaucoma, 6(6), 567-569. ()
    4. Mai AP, Wirostko B, Fitch S, Hansen K, Imbrescia W, Stagg BC (2023). Using Technology to Address Ophthalmic Technician Shortages in Glaucoma Clinics. Ophthalmol Glaucoma, 6(6), 567-569. ()

    Letter

    1. Delsoz M, Raja H, Madadi Y, Tang AA, Wirostko BM, Kahook MY, Yousefi S (2024). A Response to: Letter to the Editor Regarding "The Use of ChatGPT to Assist in Diagnosing Glaucoma Based on Clinical Case Reports.". [Letter to the editor]. Ophthalmol Ther. ()
    2. Wirostko B, Mann B, Stirland D (2020). Re: "Cross-Linked Hyaluronic Acid as Tear Film Substitute" by Posarelli et al. (J Ocul Pharmacol Ther 2019;35(7):381-387). [Letter to the editor]. J Ocul Pharmacol Ther, 36(4), 205. ()

    Abstract

    1. Amakiri N, Branham K, Jayasundera TK, Andrews, Chris A, Milentijevic D, Narayanan D, Johnson T, Jensen J, Wirostko BM, Stein JD (2023). Leveraging the Sight Outcomes Research Collaborative (SOURCE) Repository to Identify Patients with RPGR-Related Retinitis Pigmentosa  [Abstract]. 64(8), 4664.
    2. Chang M, Harris A, Zaid M, Sala L, Szopos M, Lapin S, Kuvin J, Ciulla TA, Pasquale LR, Wirostko BM, Verticchio V, Alice C, Antman G, Siesky BA, Guidoboni G (2023). The Impact of reduced left ventricular contractility on retinal perfusion, ARVO 2023 [Abstract]. 64(8), 1997.
    3. Kellner, R, Harris A, Rosen RB, Wirostko BM, Siesky BA, Verticchio V, Alice C, Coleman-Beli JC, Tessone I, Chang M, Fabczak-Kubicka A, Antman G (2023). Non-glaucomatous persons with diabetes have reduced macular capillary density potentially elevating the risk for glaucoma [Abstract]. 64(8), 4721.
    4. Kazemi A, Wirostko B, Fautsch M, Htoo T, Sit AJ (2023). Diurnal Variations in Episcleral Venous Pressure  [Abstract]. 64(8), 3473.
    5. Johnson T, Wirostko B, Stein J, Stagg B, Amakiri N, Jensen J (2023). Understanding the Disease Course of RPGR-Linked vs. RP2-Linked Retinitis Pigmentosa, ARVO 2023 [Abstract]. 64(8), 4667.

    Other

    1. (2023). Glaucoma Under Pressure, The Ophthalmologist July/August 2023. The Ophthalmologist.

    Patent

    1. Wiroskto, Barbara for Jade Therapeutics, LLC (2013). Ocular Drug Delivery System - including a composition in which a formulation having an active agent (e.g. HDH,rHGH or an HDH mimic) that increases insulin growth factor (IGF) or that alters insulin grouwth factor binding protein (IGFBP) in a subject is dispersed in a pharmaceutical carrier. The composition is configured for placement in, around or on an eye of the subject, and the composition provides controlled release of an amount of the active agent to the eye effective to promote ocular surface and corneal neural regeneration and wound healing. U.S. Patent No. WO/2013/158661 (PCT/US2013/036807). Washington, D.C.:U.S. Patent and Trademark Office.
    2. Wirostko, Barbara for Jade Therapeutics (2013). Application #4-HGH for Ocular Diseases. U.S. Patent No. 61/956,070. Washington, D.C.:U.S. Patent and Trademark Office.
    3. Wirostko, Barbara for Jade Therapeutics, LLC (2012). Application #2 - Dermal Wound Healing. U.S. Patent No. 61/58, 1845. Washington, D.C.:U.S. Patent and Trademark Office.
    4. Wirostko, Barbara for Jake Therapeutics (2012). Application #3 -Corneal Re-Innervation. U.S. Patent No. 3246-005. Washington, D.C.:U.S. Patent and Trademark Office.
    5. Wirostko, Barbara for Jade Therapeutics, LLC (2011). Application #1- Corneal Wound Healing. U.S. Patent No. 61/62,4730. Washington, D.C.:U.S. Patent and Trademark Office.

  • News & Podcasts

    News